ClinVar Miner

Submissions for variant NM_000153.4(GALC):c.195+1G>A

gnomAD frequency: 0.00001  dbSNP: rs1009872980
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000498766 SCV000589854 likely pathogenic not provided 2016-06-14 criteria provided, single submitter clinical testing The c.195+1 G>A splice site variant destroys the canonical splice donor site of intron 1. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Although this variant has no been previously reported to our knowledge, it is interpreted to be likely pathogenic.
Counsyl RCV000666305 SCV000790575 likely pathogenic Galactosylceramide beta-galactosidase deficiency 2017-03-29 criteria provided, single submitter clinical testing
Invitae RCV000666305 SCV001582066 pathogenic Galactosylceramide beta-galactosidase deficiency 2023-11-15 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 1 of the GALC gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALC are known to be pathogenic (PMID: 7437911, 9272171, 16607461). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with Krabbe disease (PMID: 28598007). This variant is also known as c.147+1G>A. ClinVar contains an entry for this variant (Variation ID: 432166). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Revvity Omics, Revvity RCV000498766 SCV002021212 pathogenic not provided 2019-05-20 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.